At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 15 target
Drug / intervention
AlloRxbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Lupus
The Foundation for Orthopaedics and Regenerative Medicine·interventional·Posted Aug 24, 2021·Updated Apr 8, 2025
In Brief
A Phase 1 clinical trial evaluating AlloRx for Lupus. Currently recruiting, targeting 15 participants across 2 sites in 2 countries.
Detailed Summary
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Lupus
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLupus
CountriesAntigua and Barbuda, Greece
Collaborators--
Timeline
Phase 1Recruiting
2022202320242025202620272028
First PostedAug 2021
Enrollment StartDec 2025
TodayJul 2026
Primary CompletionOct 2028
First PostedAug 24, 2021
Enrollment StartDec 1, 2025
Primary CompletionOct 1, 2028
TodayJul 1, 2026
Enrollment to primary: 2.8 yearsPosted 4.9 years agoPrimary completion in 2.3 years
Interventions
AlloRxbiological
cultured allogeneic adult umbilical cord derived mesenchymal stem cells